General information

TerugBetaalRegeling Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF & HFpEF) has been stopped. 

From July 1st 2023 onwards, Forxiga® (dapagliflozin) 10 mg for symptomatic chronic heart failure is fully reimbursement by the health insurer. Therefore the TerugBetaalRegeling (TBR) Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF & HFpEF) has been stopped. The manufacturer of this medicine has reimbursed the costs of the personal contribution to the patient from February 13th until June 30th 2023. 

For a complete reimbursement overview of Forxiga® (dapagliflozin) 10 mg, click here

For a digital reimbursement guide of Forxiga® (dapagliflozine) 10 mg, click here

Dose Forxiga® 10mg
Type Tablets
Active ingredient DAPAGLIFLOZINE

Reimbursement

Conditions

Declaration with an issue date between the above dates can still be submitted until November 1st 2023. 

Who can submit a claim

  1. Patients or their caregiver can claim the Personal Contribution for Forxiga® (dapagliflozine) 10mg online or by mail.
  2. Pharmacists can only claim this medicine online on behalf of the patient.

From when till when can you submit a claim

Declaration with an issue date between the above dates can still be submitted until November 1st 2023. 

Submit a claim online

Patients and pharamcists can claim online and will receive the reimbursement within 5 working days.

Read our tips on how to submit a claim online

Login & Submit a Claim          

Open an Online Account (Patients) Open an Online account (Pharmacists)


Submit a claim by post

Patients can claim by post and will receive their reimbursement within 15 working days.

Tips on how to submit your claim by post

Please mail the Claim Form and attachments to:

TBR Nederland
Postbus 8011
1180 LA Amstelveen 

NL-10666 prod. 02/2023
You are currently offline. Some pages or content may fail to load.